Introduction
One should remark that menopause is one of the causes of bone loss and an increased risk of osteoporosis. Accordingly, hormone replacement therapy (HRT) permits achieving the most promising results in strengthening the body and reducing the likelihood of “ruptures.” In this situation, it is reasonable to assume that taking Premarin as part of HRT preserved the patient’s bone mineral density (BMD) at all skeletal sites. The objectivity and reliability of this assumption are evidenced by the investigation focusing on several positive effects of menopause hormone therapy (MHT) on minimizing the risks of fractures and osteoporosis, as well as supporting and enhancing BMD (Zuo et al., 2019). At first sight, the woman’s state of health is in relatively good condition.
The Continuation of HRT
As practice shows, discontinuation of HRT is possible in case of the disappearance of symptoms of menopause, such as hot flashes, chills, vaginal dryness, irregular periods, and much more. Consequently, it would be appropriate not to stop taking HRT abruptly but gradually reduce the dose (Hormone replacement therapy (HRT), 2022). Nevertheless, before giving an accurate answer, it is necessary to check the general state of the woman’s health, family history, and bone density in the anamnesis since, in some cases, it is possible to continue HRT after 60 years.
Plan for Care
The care plan should appeal to control blood pressure and blood sugar levels, regular physical activity, and adherence to a low-fat diet, such as the Mediterranean diet. In general, statins will be a great option in contrast to or in addition to hormone replacement. Moreover, based on the case, regular lipid screening should be additionally carried out if there are no other risk factors for cardiovascular diseases.
References
Hormone replacement therapy (HRT). (2022). NHS 24. Web.
Zuo, H., Sun, A., Gao, L., Xue, W., Deng, Y., Wang, Y., Zhu S., Ma X., & Xin, H. (2019). Effect of menopausal hormone therapy on bone mineral density in Chinese women: A 2-year, prospective, open-label, randomized-controlled trial. Medical Science Monitor: International Medical Journal of Experimental and Clinical Research, 25, 819-826. Web.